No back seat for a progression event-K-RAS as a therapeutic target in CRC
Emily J Poulin1,2,3, Kevin M Haigis1,2,3
1Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.
Abstract:
KRAS is the most frequently mutated oncogene in human cancer and plays a central, although poorly understood, role in colorectal cancer (CRC) progression. In this issue of Genes & Development, Boutin and colleagues (pp. 370-382) present a new mouse model of CRC in which the expression of oncogenic K-RAS is regulated by doxycycline. Using this model, they demonstrate that continued expression of oncogenic K-RAS is required for the survival of primary and metastatic colon cancers and that oncogenic K-RAS activates TGF-β signaling to promote tumor invasion and metastasis.
Related Concept Videos
The Ras Gene
Ras is a...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Targeted Cancer Therapies
There are several types of targeted therapies against...
Abnormal Proliferation
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
mTOR Signaling and Cancer Progression
The mTOR pathway or the...


